Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update

@article{Bacigalupo2015UnmanipulatedHB,
  title={Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update},
  author={Andrea Bacigalupo and Alida Dominietto and Anna Ghiso and Carmen Di Grazia and Teresa Lamparelli and Francesca Gualandi and Stefania Bregante and M Teresa van Lint and Simona Geroldi and Silvia Luchetti and Raffaella Grasso and Samantha Pozzi and Nicoletta Colombo and Elisabetta Tedone and Riccardo Varaldo and A M Raiola},
  journal={Bone Marrow Transplantation},
  year={2015},
  volume={50},
  pages={S37-S39}
}
This is a report of 148 patients with hematologic malignancies who received an unmanipulated haploidentical bone marrow transplant (BMT), followed by post-transplant high-dose cyclophosphamide (PT-CY). All patients received a myeloablative conditioning consisting of thiotepa, busulfan, fludarabine (n=92) or TBI, fludarabine (n=56). The median age was 47 years (17–74); 47 patients were in first remission (CR1), 37 in second remission (CR2) and 64 had an active disease; all patients were first… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 12 references

Unmanipulated bone marrow transplantation from haploidentical related donors for patients with high risk hematologic malignancies

  • P Di Bartolomeo, S Santarone, +4 authors P Olioso
  • Blood
  • 2013

and marrow transplantation can achieve comparable outcomes with HLA - identical sibling transplantation

  • L Luznik, PV O'Donnell, HJ Symons, AR Chen, MS Leffell, M Zahurak
  • 2006

Similar Papers

Loading similar papers…